BPC-157 vs Thymosin Alpha-1

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

BPC-157

Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.

Full details →

Thymosin Alpha-1

Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.

Full details →

Side-by-Side Comparison

Aspect	BPC-157	Thymosin Alpha-1
Dose Range	250 mcg–500 mcg	1.6 mg–3.2 mg
Frequency	2x daily	Less than daily
Cycle Length	4–6 weeks	4–12 weeks
Route	subcutaneous	subcutaneous
Mechanism	BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels.	Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes.
Typical Dosage	Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied.	Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary.
Administration	Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable.	Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols.
Side Effects	Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses.	Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue.
Best For	Muscle Growth Recovery & Healing	Recovery & Healing